Anti-West Nile Virus (Clone: WNV-96)

Sequenced from human survivors of West Nile.

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.

Standard Overnight on Blue Ice.

ELISA
FC

WNV-96 activity is directed against the β-Ladder, spaghetti loop of NS1.

West Nile Virus (WNV) is a mosquito-borne, enveloped, positive-stranded RNA flavivirus¹. Flavivirus nonstructural protein NS1 has been proposed as an antibody target to avoid antibody-dependent enhancement². NS1 is a 46-55 kDa glycoprotein that is expressed as a dimer on the cell surface and as a soluble hexamer in the extracellular space and in circulation during infection. WNV NS1 dimer consists of a ß-roll, wing, and ß-ladder.

1. Goo L, Debbink K, Kose N, et al. Nat Microbiol. 4(1):71-77. 2019.
2. Wessel AW, Doyle MP, Engdahl TB, et al. mBio. 12(5):e0244021. 2021.